Treatment of aplastic anemia with antithymocyte globulin, cyclosporin A, methylprednisolone, danazole and recombinant human granulocyte‐colony stimulating factor

Shichino, Hiroyuki; Mugishima, Hideo; Takamura, Mayumi; Shimada, Tadashi; Suzuki, Takashi; Chin, Motoaki; Harada, Kensuke; Ryo, Sigeo; Kojima, Seiji

doi:10.1111/j.1442-200x.1996.tb03724.x

Cited by 3 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…for 6 months, with dose adjustment to maintain a serum trough concentration of 100-200 ng/ml), and danazol (5 mg/kg p.o. for 6 months) [15]. No adverse effects were observed except for transient Coombs' positive hemolysis, which recovered without specific treatment.…”

Section: Detection Of the B19 Virus Antigen And Genomementioning

confidence: 87%

Severe aplastic anemia associated with human parvovirus B19 infection in a patient without underlying disease

Osaki

Matsubara

Iwasaki

et al. 1999

Annals of Hematology

View full text Add to dashboard Cite

Human parvovirus B19 (B19 virus) infection is known to induce aplastic crisis in patients with hemolytic anemia. In healthy subjects, B19 infection may sometimes cause mild pancytopenia, but these changes are transient and recovery is spontaneous. We report the first case of aplastic anemia in a previously healthy boy without any underlying diseases, following asymptomatic infection with the B19 virus. Laboratory examination initially showed thrombocytopenia, mild leukopenia in the peripheral blood, and severe hypoplastic bone marrow. Since pancytopenia developed and worsened progressively, immunosuppressive therapy was given, resulting in a complete remission. Despite the lack of an infectious prodrome, serological and histological analysis revealed an underlying infection with the B19 virus. Thus, B19 virus infection must be considered one of the causes of aplastic anemia in patients without underlying hemolytic anemia and an apparent episode of the viral infection.

show abstract

Section: Detection Of the B19 Virus Antigen And Genomementioning

confidence: 87%

Severe aplastic anemia associated with human parvovirus B19 infection in a patient without underlying disease

Osaki

Matsubara

Iwasaki

et al. 1999

Annals of Hematology

View full text Add to dashboard Cite

show abstract

“…Danazol, a synthetic attenuated androgen, has been used widely for anemia in variety of disorders, including pure red cell aplasia, autoimmune hemolytic anemia, aplastic anemia, and IMF [9][10][11][12][13][14]. Cervantes et al [15] reported 30 IMF patients who took danazol for 20.5 months and 11 patients (37%) achieved complete remission (transfusion cessation with normal hemoglobin level).…”

Section: Discussionmentioning

confidence: 99%

Dramatic remission of anemia after thymectomy in a patient of idiopathic myelofibrosis with thymoma

et al. 2007

View full text Add to dashboard Cite

Anemia is one of the characteristics of idiopathic myelofibrosis (IMF), and malignant thymoma is usually associated with various hematologic disorders, including anemia, pancytopenia, and hypogammaglobulinemia. However, the relationship between IMF and malignant thymoma has not been published before. Here, we report a 48-year-old woman who was initially diagnosed of IMF with severe anemia and transfusion dependent. Five years later, malignant thymoma was found when she was examined for chronic cough. After performing extended thymectomy, her anemia dramatically recovered to normal and sustained for 2 years till last follow-up. Her splenomegaly and myelofibrosis were also improved. We hypothesized that her malignant thymoma induced the progression of IMF, especially in anemia.

show abstract

“…CYA and antithymocyte globulin (ATG) are thought to inhibit the functioning of the T‐cells that suppress stem cells [10]. Immunosuppressive therapy with G‐CSF for the treatment of aplastic anemia was reported by Bacigalupo et al [16] and by Shichino et al [17]. Furthermore, high‐dose G‐CSF therapy [18] and combination therapy with G‐CSF and rhEPO [19] are advocated for the successful treatment of severe aplastic anemia.…”

Section: Discussionmentioning

confidence: 99%

Successful cytokine treatment of aplastic anemia following living‐related orthotopic liver transplantation for non‐A, non‐B, non‐C hepatitis

Sato¹,

Fuchinoue²,

Abe³

et al. 1999

Clinical Transplantation

View full text Add to dashboard Cite

The relationship between aplastic anemia and viral hepatitis is well recognized, and such patients usually have a high mortality. We successfully treated a case of aplastic anemia following living-related orthotopic liver transplantation (LROLT) for non-A, non-B, non-C hepatitis. A 2-yr-old boy with fulminant hepatic failure from non-A, non-B, non-C hepatitis received LROLT. Before transplantation, he had pancytopenia which was probably hepatitis associated, and viral suppression was suspected after bone marrow (BM) biopsy. After the transplantation, he developed progressive pancytopenia and a diagnosis of aplastic anemia was made via BM biopsy. With immunosuppressant agents (cyclosporine, methylprednisolone), cytokine therapy (granulocyte-colony stimulating factor (G-CSF), macrophage-colony stimulating factor (M-CSF), recombinant human erythropoietin (rhEPO)) was effectual and the patient recovered from pancytopenia. He was discharged from the hospital 57 d after the liver transplantation and remains well 1 yr after LROLT. Combined cytokine therapy with high doses of G-CSF, M-CSF and rhEPO appeared to be effective in the treatment of aplastic anemia following liver transplantation for non-A, non-B, non-C hepatitis. Since M-CSF activates macrophages, it may have contributed to the graft rejection. Careful consideration should be given to the use of high-dose M-CSF in liver transplant patients.

show abstract

Treatment of aplastic anemia with antithymocyte globulin, cyclosporin A, methylprednisolone, danazole and recombinant human granulocyte‐colony stimulating factor

Cited by 3 publications

References 13 publications

Severe aplastic anemia associated with human parvovirus B19 infection in a patient without underlying disease

Severe aplastic anemia associated with human parvovirus B19 infection in a patient without underlying disease

Dramatic remission of anemia after thymectomy in a patient of idiopathic myelofibrosis with thymoma

Successful cytokine treatment of aplastic anemia following living‐related orthotopic liver transplantation for non‐A, non‐B, non‐C hepatitis

Contact Info

Product

Resources

About